proTAME 5μM R04 exp187 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== proTAME 5μM R04 exp187 ======
==== Mechanism of Action ====
Inhibits APC/C interaction with Cdc20/Cdh1 substrate recognition cofactors
  * **<color #00a2e8>Class / Subclass 1:</color>** Proteostasis / E3 ubiquitin ligase inhibitor
  * **<color #00a2e8>Class / Subclass 2:</color>** Cell Cycle / Mitotic Inhibitor



==== Technical Notes ====
<accordion collapsed='true'>
<panel title='Compound References' collapsed='true'>
    * **<color #00a2e8>PubChem Name:</color>** %%Methyl (2S)-5-[bis[(2-phenylacetyl)oxymethoxycarbonylamino]methylideneamino]-2-[(4-methylphenyl)sulfonylamino]pentanoate%%
    * **<color #00a2e8>Synonyms:</color>** N/A
    * **<color #00a2e8>CAS #:</color>** 1362911-19-0
    * **<color #00a2e8>PubChem CID:</color>** [[https://pubchem.ncbi.nlm.nih.gov/compound/56924780|56924780]]
    * **<color #00a2e8>IUPAC:</color>** %%methyl (2S)-5-[bis[(2-phenylacetyl)oxymethoxycarbonylamino]methylideneamino]-2-[(4-methylphenyl)sulfonylamino]pentanoate%%
    * **<color #00a2e8>INCHI Name:</color>** InChI=1S/C34H38N4O12S/c1-24-15-17-27(18-16-24)51(44,45)38-28(31(41)46-2)14-9-19-35-32(36-33(42)49-22-47-29(39)20-25-10-5-3-6-11-25)37-34(43)50-23-48-30(40)21-26-12-7-4-8-13-26/h3-8,10-13,15-18,28,38H,9,14,19-23H2,1-2H3,(H2,35,36,37,42,43)/t28-/m0/s1
    * **<color #00a2e8>INCHI Key:</color>** MHYOVHULCQSDRZ-NDEPHWFRSA-N
    * **<color #00a2e8>Molecular Weight:</color>** 726.8
    * **<color #00a2e8>Canonical SMILES:</color>** CC1=CC=C(C=C1)S(=O)(=O)NC(CCCN=C(NC(=O)OCOC(=O)CC2=CC=CC=C2)NC(=O)OCOC(=O)CC3=CC=CC=C3)C(=O)OC
    * **<color #00a2e8>Isomeric SMILES:</color>** CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCN=C(NC(=O)OCOC(=O)CC2=CC=CC=C2)NC(=O)OCOC(=O)CC3=CC=CC=C3)C(=O)OC
    * **<color #00a2e8>Molecular Formula:</color>** C34H38N4O12S
{{:chemogenomics:structures:chem-0120.svg?nolink}}
</panel>


<panel title='Compound Supplier' collapsed='true'>
    * **<color #00a2e8>Supplier Name:</color>** Boston Biochem
    * **<color #00a2e8>Catalog #:</color>** I-440
    * **<color #00a2e8>Lot #:</color>** N/A
</panel>


<panel title='Compound Characterization' collapsed='true'>
    * **<color #00a2e8>LCMS:</color>** Tr 1.24 min, m/z 203-
</panel>


<panel title='Dose Response Curve' collapsed='true'>
    * **<color #00a2e8>Platform ID:</color>** proTAME
    * **<color #00a2e8>Min:</color>** -10.5981; **<color #00a2e8>Max:</color>** 74.8880
{{:chemogenomics:dose_response:dr_233.png?nolink&500 |}}
\\ 
\\ 
\\ 
\\ 
|< 300px 100px 200px >|
^ IC   ^ Concentration (µM) ^
| IC10  |N/A    |
| IC20  |16.3280    |
| IC30  |17.0911    |
| IC40  |17.7431    |
| IC50  |18.3634    |
| IC60  |N/A    |
| IC70  |N/A    |
| IC80  |N/A    |
| IC90  |N/A    |
\\ 
</panel>
</accordion>
==== Screen Summary ====
    * **<color #00a2e8>Round</color>**: 04
    * **<color #00a2e8>Dose</color>**: 5µM
    * **<color #00a2e8>Days of incubation</color>**: 8
    * **<color #00a2e8>Doublings</color>**: 6.7
    * **<color #00a2e8>Numbers of reads</color>**: 19315630


==== Screen Results ====


^Sensitive/Resistant hits (FDR<0.05)^CRANKS^Score Plot^Top 30 Genes^Screen Similarity^Top 30 Sensitive GO terms^Top 30 Resistant GO terms^
|12/3|<color #e85500>[[https://files.tyerslab.com/files/public/chemogenomics/cranks/proTAME_5uM_Round-4_exp187.txt|Scores]]</color>|<button type="primary" size="sm" modal="ScorePlot">View</button>|<button type="primary" size="sm" modal="modal_hits">View</button>|<button type="primary" size="sm" modal="modal_screen_similarity">View</button>|<button type="primary" size="sm" modal="modal_go_sensitive">View</button>|<button type="default" size="sm" modal="modal_go_resistant">View</button>|
<modal id='ScorePlot' size='lg' title='proTAME 5μM R04 exp187'>
{{:chemogenomics:cranks_plots:exp187.png?nolink}}
</modal>


<modal id="modal_hits" size="sm" title="Top 30 S/R Genes">
^Gene^CRANKS Score^FDR^
|[[:human_genes:T:TRIP13|TRIP13]]|-4.23|<0.01|
|[[:human_genes:M:MAD2L1BP|MAD2L1BP]]|-3.96|<0.01|
|[[:human_genes:A:ANAPC7|ANAPC7]]|-3.96|<0.01|
|[[:human_genes:S:SLC18B1|SLC18B1]]|-3.78|<0.01|
|[[:human_genes:A:ARL1|ARL1]]|-3.52|<0.01|
|[[:human_genes:U:UBE2S|UBE2S]]|-3.39|<0.01|
|[[:human_genes:K:KDSR|KDSR]]|-3.27|<0.01|
|[[:human_genes:A:ANAPC16|ANAPC16]]|-2.90|<0.01|
|[[:human_genes:G:GCLM|GCLM]]|-2.67|0.01|
|[[:human_genes:Z:ZFAT|ZFAT]]|-2.66|0.03|
|[[:human_genes:N:NPRL2|NPRL2]]|-2.60|0.02|
|[[:human_genes:P:PGGT1B|PGGT1B]]|-2.60|0.02|
|[[:human_genes:A:ANAPC13|ANAPC13]]|-2.54|0.05|
|[[:human_genes:T:TCF4|TCF4]]|-2.39|0.05|
|[[:human_genes:A:ALG3|ALG3]]|-2.38|0.05|
|[[:human_genes:A:ALDH18A1|ALDH18A1]]|-2.37|0.05|
|[[:human_genes:M:MAPK14|MAPK14]]|-2.36|0.05|
|[[:human_genes:A:ALG6|ALG6]]|-2.35|0.05|
|[[:human_genes:A:ANAPC15|ANAPC15]]|-2.34|0.15|
|[[:human_genes:R:RUNX3|RUNX3]]|-2.33|0.05|
|[[:human_genes:K:KCTD5|KCTD5]]|-2.33|0.05|
|[[:human_genes:M:MCM9|MCM9]]|-2.31|0.05|
|[[:human_genes:C:C17orf70|C17orf70]]|-2.29|0.06|
|[[:human_genes:M:MCTS1|MCTS1]]|-2.23|0.08|
|[[:human_genes:S:SEPSECS|SEPSECS]]|-2.22|0.14|
|[[:human_genes:U:UBE2C|UBE2C]]|-2.21|0.09|
|[[:human_genes:G:GTF3C6|GTF3C6]]|-2.19|0.09|
|[[:human_genes:S:SEC62|SEC62]]|-2.17|0.16|
|[[:human_genes:C:C1orf27|C1orf27]]|-2.15|0.11|
|[[:human_genes:K:KIAA1432|KIAA1432]]|-2.12|0.12|
|[[:human_genes:G:GPR108|GPR108]]|1.99|0.50|
|[[:human_genes:P:PCDHB5|PCDHB5]]|2.00|0.47|
|[[:human_genes:I:INTS5|INTS5]]|2.01|0.60|
|[[:human_genes:R:RPL34|RPL34]]|2.01|0.62|
|[[:human_genes:Z:ZP3|ZP3]]|2.05|0.47|
|[[:human_genes:D:DDX41|DDX41]]|2.05|0.47|
|[[:human_genes:C:CHCHD5|CHCHD5]]|2.08|0.46|
|[[:human_genes:S:SRSF3|SRSF3]]|2.09|0.47|
|[[:human_genes:N:NID2|NID2]]|2.13|0.47|
|[[:human_genes:R:RPL37A|RPL37A]]|2.14|0.62|
|[[:human_genes:D:DDX47|DDX47]]|2.21|0.67|
|[[:human_genes:N:NOP16|NOP16]]|2.21|0.57|
|[[:human_genes:P:PCDHB1|PCDHB1]]|2.22|0.30|
|[[:human_genes:C:CKAP5|CKAP5]]|2.24|0.57|
|[[:human_genes:M:MYB|MYB]]|2.24|0.50|
|[[:human_genes:H:HIVEP3|HIVEP3]]|2.26|0.47|
|[[:human_genes:W:WDR75|WDR75]]|2.30|0.47|
|[[:human_genes:M:MYH13|MYH13]]|2.36|0.46|
|[[:human_genes:T:TMEM74|TMEM74]]|2.37|0.15|
|[[:human_genes:S:SLC24A2|SLC24A2]]|2.37|0.46|
|[[:human_genes:P:PARP3|PARP3]]|2.48|0.09|
|[[:human_genes:R:RNF112|RNF112]]|2.64|0.09|
|[[:human_genes:S:SART1|SART1]]|2.72|0.50|
|[[:human_genes:T:TBC1D3I|TBC1D3I]]|2.83|0.47|
|[[:human_genes:T:TBC1D3E|TBC1D3E]]|2.84|0.47|
|[[:human_genes:T:TBC1D3K|TBC1D3K]]|2.84|0.47|
|[[:human_genes:T:TBC1D3L|TBC1D3L]]|2.85|0.47|
|[[:human_genes:Z:ZNF653|ZNF653]]|3.05|0.01|
|[[:human_genes:N:NCEH1|NCEH1]]|4.29|<0.01|
|[[:human_genes:A:ABHD6|ABHD6]]|4.90|<0.01|
</modal>


<modal id="modal_screen_similarity" size="lg" title="Correlated Screens">
^Screen^Correlation^Plot^
|[[:results:exp177|Apcin 25μM plus proTAME 2μM R04 exp177]]|0.148|<button type="primary" size="small" modal="1">View</button>|
|[[:results:exp176|Apcin 50 to 100μM on day4 R04 exp176]]|0.095|<button type="primary" size="small" modal="2">View</button>|
|[[:results:exp77|Prochlorperazine 5.2μM R02 exp77]]|0.062|<button type="primary" size="small" modal="3">View</button>|
|[[:results:exp169|BH1 1μM R04 exp169]]|0.056|<button type="primary" size="small" modal="4">View</button>|
|[[:results:exp185|L-BMAA 500 to 750μM on day4 R04 exp185]]|0.054|<button type="primary" size="small" modal="5">View</button>|
|[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|0.054|<button type="primary" size="small" modal="6">View</button>|
|[[:results:exp247|UM0130462 0.025 to 0.035μM day4 R05 exp247]]|0.052|<button type="primary" size="small" modal="7">View</button>|
</modal>


<modal id="1" size="lg" title="Apcin 25μM plus proTAME 2μM R04 exp177  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp177_vs_exp187.png?nolink |}}
</modal>

<modal id="2" size="lg" title="Apcin 50 to 100μM on day4 R04 exp176  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp176_vs_exp187.png?nolink |}}
</modal>

<modal id="3" size="lg" title="Prochlorperazine 5.2μM R02 exp77  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp187_vs_exp77.png?nolink |}}
</modal>

<modal id="4" size="lg" title="BH1 1μM R04 exp169  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp169_vs_exp187.png?nolink |}}
</modal>

<modal id="5" size="lg" title="L-BMAA 500 to 750μM on day4 R04 exp185  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp185_vs_exp187.png?nolink |}}
</modal>

<modal id="6" size="lg" title="Ixabepilone 0.004 to 0.005μM on day4 R04 exp184  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp184_vs_exp187.png?nolink |}}
</modal>

<modal id="7" size="lg" title="UM0130462 0.025 to 0.035μM day4 R05 exp247  vs  proTAME 5μM R04 exp187">
{{:chemogenomics:comparison_plots:exp187_vs_exp247.png?nolink |}}
</modal>



<modal id="modal_go_sensitive" size="lg" title="Top 30 sensitive GO terms">
^GO Term^Fold Change^Genes^
|anaphase-promoting complex|184.16|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,UBE2C|
|anaphase-promoting complex-dependent catabolic process|184.16|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,UBE2C|
|positive regulation of mitotic metaphase/anaphase transition|141.66|MAD2L1BP,ANAPC7,UBE2C|
|positive regulation of metaphase/anaphase transition of cell cycle|131.54|MAD2L1BP,ANAPC7,UBE2C|
|positive regulation of mitotic sister chromatid separation|108.33|MAD2L1BP,ANAPC7,UBE2C|
|protein K11-linked ubiquitination|87.69|ANAPC7,UBE2S,ANAPC13,UBE2C|
|nuclear ubiquitin ligase complex|85.65|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,UBE2C|
|regulation of mitotic sister chromatid separation|52.92|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|regulation of meiotic cell cycle|48.72|TRIP13,ANAPC7,ANAPC16,ANAPC13,ANAPC15|
|regulation of chromosome separation|42.04|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|regulation of mitotic metaphase/anaphase transition|34.49|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|regulation of metaphase/anaphase transition of cell cycle|33.36|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|regulation of sister chromatid segregation|29.80|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|regulation of mitotic nuclear division|26.23|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|regulation of chromosome segregation|24.36|TRIP13,MAD2L1BP,ANAPC7,ANAPC15,UBE2C|
|cullin-RING ubiquitin ligase complex|23.87|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,KCTD5,UBE2C|
|ubiquitin ligase complex|13.82|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,KCTD5,UBE2C|
|proteasome-mediated ubiquitin-dependent protein catabolic process|12.45|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,KCTD5,UBE2C|
|proteasomal protein catabolic process|11.31|ANAPC7,UBE2S,ANAPC16,ANAPC13,ANAPC15,KCTD5,UBE2C|
</modal>
<modal id="modal_go_resistant" size="lg" title="Top 30 resistant GO terms">No GO term hits below threshold. (FDR <0.05)</modal>